Clinical investigationWill the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?☆
References (13)
- et al.
Unstable angina: diagnosis and management
(1994) - et al.
Low molecular-weight heparins for unstable angina: a better mousetrap?
Circulation
(1997) - et al.
A comparison of lowmolecular-weight heparin with unfractionated heparin for unstable coronary artery disease
N Engl J Med
(1997) - et al.
One year follow-up of the ESSENCE trial (enoxaparin vs heparin in unstable angina/non-Q wave myocardial infarction): sustained clinical benefit
Can J Cordial
(1998) - et al.
Economic assessment of low molecular weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial
Circulation
(1998) - et al.
Users' guides to the medical literature, XIII: how to use an article on economic analysis of clinical practice, Part B: what are the results and will they help me in caring for my patients?
JAMA
(1997)
Cited by (55)
Multicenter study of health care cost of patients admitted to hospital with Staphylococcus aureus bacteremia: Impact of length of stay and intensity of care
2015, American Journal of Infection ControlCitation Excerpt :The primary outcome was total cost of inpatient care for each patient using 2010 Canadian dollars. This was determined using the Ontario Case Costing Initiative (OCCI) methodology.17-20 This methodology is based on the Canadian Institute for Health Information Management Information Systems Guidelines and Ontario's Ministry of Health and Long-Term Care's Healthcare Reporting Standards.
The Use of Antithrombotics for Acute Coronary Syndromes in the Emergency Department: Considerations and Impact
2007, Progress in Cardiovascular DiseasesCitation Excerpt :In light of the recent trial data from ExTRACT-TIMI 25 and OASIS-6, future guidelines are likely to take into account the evidence on the clinical benefit to STEMI patients receiving enoxaparin compared with those receiving UFH or the clinical benefit of fondaparinux compared with UFH in STEMI patients treated with a noninvasive strategy. In patients with UA or NSTEMI, an AHA statement has prepared an algorithm from the ACC/AHA guidelines for use in the emergency room (Fig. 1), which states that antiplatelet therapy with aspirin or clopidogrel should be initiated as soon as possible.36 Such patients should also receive heparin therapy: enoxaparin is considered preferable to UFH in the absence of renal failure, unless CABG surgery is planned within 24 hours.34
Economic evaluation in critical care medicine
2006, Journal of Critical CareExcessive Hemorrhage after Dental Extractions Using Low-Molecular-Weight Heparin (Lovenox) Anticoagulation Therapy
2004, Journal of Oral and Maxillofacial Surgery
- ☆
Supported in part by a grant from Rhone-Poulenc Rorer Canada Inc. Dr O'Brien is a recipient of a career award in health sciences from the Medical Research Council and Prescription Drug Manufacturers Association of Canada.